Real World Experience of Denosumab Treatment in the Belfast Osteoporosis Service
| Autor: | C P, Moran, S, English, Tro, Beringer, J R, Lindsay |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Aged
80 and over Male Bone Density Conservation Agents Databases Factual Age Factors Northern Ireland Middle Aged Prognosis Risk Assessment Severity of Illness Index Statistics Nonparametric Cohort Studies Absorptiometry Photon Fractures Spontaneous Sex Factors Treatment Outcome Bone Density Clinical Paper Humans Osteoporosis Female Denosumab Aged Retrospective Studies |
| Zdroj: | The Ulster Medical Journal |
| ISSN: | 2046-4207 |
| Popis: | Osteoporosis is a significant global health and economic burden associated with bone fracture, morbidity and mortality. Denosumab, a novel human monoclonal antibody second-line treatment, inhibits osteoclast-mediated bone resorption and increases bone mineral density (BMD). Treatment achieves reductions in vertebral, non-vertebral and hip fracture risk. We undertook a service evaluation to review clinical outcomes of patients treated with denosumab in an osteoporosis department that provides regional services. We identified 529 patients (95% female; mean age 72.8 years; 35-98 years), who had at least one dose of denosumab administered for the treatment of osteoporosis. The mean number of denosumab doses administered was 4.9 (range: 1 to 12). 330/529 patients had completed a baseline and post-treatment bone densitometry scan (DXA). The mean observed BMD change at around 18 months at the lumbar spine was +8.4% and at the hip was +3.5%. While the majority have transitioned to shared care administration of treatment within primary care (53%), 20% continue to attend hospital clinics to receive treatment. During follow-up, there were 66 deaths (12%). 15% switched to an alternative treatment or were discharged. This retrospective cohort study demonstrates the clinical effectiveness of denosumab in improving bone mineral density in a real life setting in an ageing, co-morbid population. There has been recent progress with adoption of shared care administration in primary care. As part of a quality improvement programme we have recently developed a dedicated denosumab database and day-case treatment clinic for those receiving treatment in secondary care. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|